Peptide News Digest

#Kff

3 stories

Industry · View digest

Medicare GLP-1 Bridge Program Marks 27 Days Since the July 1, 2026 CMS Pilot Launch That Provides All Formulations of Wegovy (Semaglutide, Novo Nordisk), the KwikPen Formulation of Zepbound (Tirzepatide, Eli Lilly), and All Formulations of Foundayo (Orforglipron, Eli Lilly) at a Capped $50 Monthly Copay for Eligible Medicare Part D Beneficiaries Through December 31, 2027; KFF Analysis Estimates Approximately 3.8 Million Medicare Beneficiaries Meet the Clinical Eligibility Criteria for the Program (~8% of the 47.5 Million Part D Enrollees Nationally), Though CMS Has Not Yet Released Actual Enrollment Data From the First Program Month

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.

Industry · View digest

KFF Cost Projection Analysis Released: Medicare GLP-1 Bridge Runs $1.3 Billion at 10% Participation to $10 Billion at 75% Participation Over the 18-Month Demonstration on a $195/Month Net Federal Payment Per Beneficiary After the $50 Copay

KFF (formerly Kaiser Family Foundation) published cost-projection detail on the Medicare GLP-1 Bridge demonstration this week that goes beyond the 3.8 million eligibility headline into the fiscal outlay Medicare actually books. The math: Medicare's net drug payment runs $195 per beneficiary per month ($245 negotiated net drug price minus the $50 patient copay). At 10% participation of the 3.8 million eligible Part D enrollees, monthly refills across the 18-month program cost Medicare roughly $1.3 billion; at 25% participation, $3.3 billion; at 50% participation, $6.7 billion; at 75% participation, $10 billion. CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first with volume ramping through Q3 and Q4 2026, suggesting the middle of the KFF range as the most probable outcome. The Bridge operates outside the standard Part D risk pool, meaning Part D plan sponsors do not carry actuarial risk for these drugs; beneficiary spending under the Bridge does not count toward the Part D $2,100 annual out-of-pocket cap for 2026. The cost-projection frame is the piece analysts and Congressional staff will use to judge Bridge success over the next 18 months.

Industry · View digest

KFF Analysis Estimates 3.8 Million Medicare Beneficiaries Eligible for GLP-1 Bridge Based on 2023 Population Data, CMS Medicare Director Chris Klomp Expects Participation in the 'Single-Digit Millions' at First, Centene Confirms Bridge Participation Despite Medicare Advantage Pilot Delay

KFF (formerly Kaiser Family Foundation) published an analysis estimating 3.8 million Medicare beneficiaries could have qualified for the Medicare GLP-1 Bridge in 2023 based on the three BMI-and-comorbidity eligibility tiers (BMI ≥35 no paired condition; BMI ≥30 with heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease). CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026 as prescriber and pharmacy familiarity grows. Centene confirmed participation in the Bridge program despite the parallel delay in its Medicare Advantage pilot. The Bridge operates outside standard Part D risk pools; Part D plan sponsors do not carry risk for eligible GLP-1 drugs under the Bridge. Net drug pricing runs $245/month with CMS covering $195 and the patient paying the $50 copay.